Search Result

Results for "

V2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Amino Acid Derivatives (2) Apoptosis (4) Arrestin (1) Autophagy (2) Bacterial (1) Calcium Channel (1) CD47 (1) CRAC Channel (1) Drug Metabolite (1) Endogenous Metabolite (3) GABA Receptor (1) Herbicide (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HIV (2) Interleukin Related (2) Isotope-Labeled Compounds (1) MHC (1) Oxytocin Receptor (5) PD-1/PD-L1 (1) Phospholipase (2) Potassium Channel (1) PROTACs (1) Reference Standards (6) Small Interfering RNA (siRNA) (4) TRP Channel (1) Vasopressin Receptor (44) Wnt (1)
By Research Areas:	Cancer (18) Cardiovascular Disease (19) Endocrinology (24) Infection (2) Inflammation/Immunology (4) Metabolic Disease (14) Neurological Disease (13)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W009724

2-Aminoethyl diphenylborinate Maximum Cited Publications 71 Publications Verification 2-APB	Calcium Channel TRP Channel CRAC Channel	Cardiovascular Disease Inflammation/Immunology
2-Aminoethyl diphenylborinate (2-APB) is a cell-permeable inhibitor of Inositol triphosphate receptor (IP3R). 2-Aminoethyl diphenylborinate also inhibits the store-operated Ca ²⁺ (SOC) channel and activates some TRP channels (V1, V2 and V3). Additionally, 2-Aminoethyl diphenylborinate has inhibitory effects on vasospasm. At high concentrations, it exhibits specific anti-inflammatory and antioxidant effects in neural tissue ^[2] .

HY-18347A

Conivaptan hydrochloride 10+ Cited Publications YM 087	Vasopressin Receptor	Cardiovascular Disease Endocrinology
Conivaptan (hydrochloride) is a non-peptide antagonist of vasopressin receptor, with K_i values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.

HY-P0049

Argipressin 5+ Cited Publications Arg8-vasopressin; AVP	Vasopressin Receptor	Neurological Disease Cancer
Argipressin (Arg8-vasopressin) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a K_d value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1.

HY-17000

Tolvaptan 15+ Cited Publications OPC-41061	Vasopressin Receptor Autophagy	Cardiovascular Disease Endocrinology Cancer
Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V₂R) antagonist with an IC₅₀ of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia ^[2].

HY-119706

Barbadin 15+ Cited Publications	Apoptosis Arrestin	Others
Barbadin is a novel and selective *β-arrestin/β2-adaptin* interaction inhibitor, has IC₅₀ values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis ^[2].

HY-14185

Lixivaptan 4 Publications Verification VPA-985; WAY-VPA 985	Vasopressin Receptor	Cardiovascular Disease Endocrinology
Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC₅₀ values of 1.2 and 2.3 nM for human and rat V2, respectively.

HY-124733A

LIT-001	Oxytocin Receptor	Neurological Disease
LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC₅₀=55 nM; K_i=226 nM). LIT-001 improves social interaction in a mouse model of autism .

HY-18346

Mozavaptan 1 Publications Verification OPC-31260	Vasopressin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment ^[2].

HY-W539944

Argipressin acetate 5+ Cited Publications Arg8-vasopressin acetate; AVP acetate	Vasopressin Receptor Apoptosis	Neurological Disease Cancer
Argipressin (Arg8-vasopressin) (acetate) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a K_d value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1 ^[2] .

HY-19381

WAY-151932 VNA-932; WAY-VNA 932	Vasopressin Receptor	Metabolic Disease Endocrinology
WAY-151932 is a vasopressin V₂-receptor agonist with IC₅₀ of 80.3 nM and 778 nM in human-V₂ binding and V_1a binding assay.

HY-P0272

Peptide T	HIV	Infection
Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

HY-14887

Fedovapagon 1 Publications Verification VA106483	Vasopressin Receptor	Metabolic Disease
Fedovapagon (VA106483) is a selective and orally active vasopressin V2 receptor (V2R) agonist with an EC₅₀ of 24 nM. Fedovapagon can be used in the research of nocturia .

HY-123593

Mozavaptan hydrochloride 1 Publications Verification OPC-31260 hydrochloride	Vasopressin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment ^[2].

HY-105685

SRX246	Vasopressin Receptor	Cardiovascular Disease Neurological Disease
SRX246 is a potent, BBB-penetrant, highly selective vasopressin 1a (V1a) receptor antagonist (K_i=0.3 nM for human V1a). SRX246 has no interaction at V1b and V2 receptors. SRX246 also displays negligible binding at 64 others receptors classes, including 35 G-proteincoupled receptors. SRX246 can be used for treatment of stress-related disorders .

HY-146272

Vasopressin V2 receptor antagonist 1	Vasopressin Receptor	Endocrinology
Vasopressin V2 receptor antagonist 1 is a vasopressin V2 receptor (V₂R) antagonist with a K_i value of 3.8 nM. Vasopressin V2 receptor antagonist 1 inhibits renal cyst formation in embryonic renal cyst models and mouse models. Vasopressin V2 receptor antagonist 1 can be used in research related to autosomal dominant polycystic kidney disease .

HY-168641

PROTAC HIF-1α degrader-1	PROTACs Apoptosis HIF/HIF Prolyl-Hydroxylase	Cancer
PROTAC HIF-1α degrader-1 (compound V2) is a potent hypoxia-inducible factor-1α (HIF-1α) PROTAC degrader with an IC₅₀ value of 7.54 µM. PROTAC HIF-1α degrader-1 shows anti-proliferative activity. PROTAC HIF-1α degrader-1 decreases the HIF-1α protein expression. PROTAC HIF-1α degrader-1 induces apoptosis. (Pink: ligand for target protein (HY-111387); black: linker (HY-W013731); Blue: E3 ligase ligand (HY-112078)) .

HY-116567

OPC-51803	Vasopressin Receptor	Metabolic Disease
OPC-51803 is an orally active nonpeptide vasopressin V₂ receptor agonist. OPC-51803 can be used for the research of micturition disorders that result in frequent micturition, such as that from polyuria, nocturnal polyuria, and some kinds of urinary incontinence .

HY-P1390

d[Cha4]-AVP	Vasopressin Receptor	Endocrinology
d[Cha4]-AVP is a potent and selective vasopressin (AVP) V1b receptor agonist with a K_i of 1.2 nM for human V1b receptor. d[Cha4]-AVP shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors ^[2].

HY-177764

Tet-v2.0-ethyl	Amino Acid Derivatives	Others
Tet-v2.0-ethyl is a tetrazine non-canonical amino acid. Tet-v2.0-ethyl can stably exist within living cells without being degraded, enabling in situ labeling of intracellular biomolecules. Tet-v2.0-ethyl is mainly used as a bioorthogonal labeling tool compound .

HY-162394

Vasopressin V2 receptor antagonist 2	Vasopressin Receptor	Metabolic Disease
Vasopressin V2 receptor antagonist 2 (Compound 33) is an antagonist of the arginine vasopressin V₂ receptor (V₂R) with a K_i value of 6.2 nM. Vasopressin V2 receptor antagonist 2 can effectively reduce cAMP levels, thereby inhibiting the growth of renal cysts[1].

HY-18347

Conivaptan YM 087 free base	Vasopressin Receptor	Cardiovascular Disease
Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function .

HY-120078

AZD2716	Phospholipase
AZD2716 is a selective *sPLA₂* (secretory phospholipase A2) inhibitor. AZD2716 significantly reduces the production of pro-inflammatory lipids by inhibiting *sPLA₂-IIa* (IC₅₀ = 10 nM), *sPLA₂-V* (IC₅₀ = 40 nM), and *sPLA₂-X* (IC₅₀ = 400 nM), thereby decreasing macrophage activation and foam cell formation. AZD2716 is promising for studying mechanisms related to atherosclerosis and inflammatory diseases associated with *sPLA₂* .

HY-116567A

(S)-OPC-51803	Endogenous Metabolite	Endocrinology
(S)-OPC-51803 is an agonist of the vasopressin V2 receptor, with activity in suppressing nocturia and urinary incontinence. (S)-OPC-51803 was evaluated in terms of biological activity and showed a stronger V2 receptor agonist effect compared to its (R)-isomer. The use of (S)-OPC-51803 may improve the patient's ability to control nocturnal polyuria .

HY-18344

Satavaptan SR 121463	Vasopressin Receptor	Metabolic Disease
Satavaptan (SR 121463) is an antagonist for vasopressin V2 receptor. Satavaptan regulates the vasopressin regulated phosphopeptides and vasopressin-mediated signaling pathway. Satavaptan is potential in ameliorating hyponatremia .

HY-109133

Pecavaptan BAY 1753011	Vasopressin Receptor	Neurological Disease Metabolic Disease
Pecavaptan, a chemical probe, is an orally active and dual antagonist of *V1a/V2* receptor (K_i=0.5 nM and 0.6 nM for human, respectively). Pecavaptan promotes an increase in urine production, which reduces the associated symptoms of water retention and edema .

HY-P0049A

Argipressin diacetate Arg8-vasopressin diacetate; AVP diacetate; ADH	Apoptosis Vasopressin Receptor	Neurological Disease Cancer
Argipressin (diacetate) (AVP (diacetate), also known as antidiuretic hormone (ADH)) is a 9 amino acid neuropeptide secreted by the posterior pituitary. Argipressin (diacetate) (AVP (diacetate)) can regulate the biological effects of fluid balance, osmolality and cardiovascular through three separate G-protein coupled receptors (GPCRs), namely Avpr1a (V1a), Avpr1b (V1b) and Avpr2 (V2). Argipressin (diacetate) (AVP (diacetate)) also have potentially important effects on centrally regulated metabolic processes .

HY-RS03483

CYP4V2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP4V2 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP4V2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP4V2 Human Pre-designed siRNA Set A CYP4V2 Human Pre-designed siRNA Set A

HY-P0272A

Peptide T TFA	HIV	Infection
Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

HY-18346R

Mozavaptan (Standard) OPC-31260 (Standard)	Vasopressin Receptor Reference Standards	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Mozavaptan (Standard) is the analytical standard of Mozavaptan. This product is intended for research and analytical applications. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment ^[2].

HY-157220

Tolvaptan phosphate ester sodium	Vasopressin Receptor	Cardiovascular Disease
Tolvaptan phosphate ester sodium, a prodrug of Tolvaptan (HY-17000), can be used in the study of cardiac edema. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation ^[2].

HY-P1390A

d[Cha4]-AVP TFA	Vasopressin Receptor	Endocrinology
d[Cha4]-AVP TFA is a potent and selective vasopressin (AVP) V1b receptor agonist with a K_i of 1.2 nM for human V1b receptor. d[Cha4]-AVP TFA shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors ^[2].

HY-121540

IWP-2-V2	Wnt	Cancer
IWP-2-V2 is a IWP-2 (HY-13912) analogue that retains activity against the Wnt/β-catenin pathway .

HY-168742

V1a/V2 antagonist 1	Vasopressin Receptor	Neurological Disease
V1a/V2 antagonist 1 (Compound 18j) is an orally active dual V1a and V2 receptor antagonist with high binding affinity for both receptors (K_i: 0.13 nM for hV1a, 0.53 nM for hV2 and 0.5 nM for mV1a; IC₅₀: 2.2 nM for hV1a). V1a/V2 antagonist 1 inhibits Oxytocin (HY-17571)-induced scratching behavior in mice .

HY-14185R

Lixivaptan (Standard) VPA-985 (Standard); WAY-VPA 985 (Standard)	Vasopressin Receptor Reference Standards	Cardiovascular Disease Endocrinology
Lixivaptan (Standard) is the analytical standard of Lixivaptan. This product is intended for research and analytical applications. Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively.

HY-109181

Lazuvapagon SK-1404; KRP-N118	Vasopressin Receptor	Others
Lazuvapagon (SK-1404) is a vasopressin V2 receptor agonist for the research of nocturia .

HY-158163

Herbicidal agent 4	Herbicide	Inflammation/Immunology
Herbicidal agent 4 (compound V-2) is an auxinic herbicidal agent. Herbicidal agent 4 may also be an immune activator while upregulating the defense genes and increasing content of jasmonic acid .

HY-P1810

c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-Agm	Vasopressin Receptor	Neurological Disease
c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-Agm is a is a potent, selective and short-acting peptidic V₂ receptor (V₂R) agonist with EC₅₀s of 0.25 and 0.05 nM for hV₂R and rV₂R, respectively .

HY-123593R

Mozavaptan hydrochloride (Standard) OPC-31260 hydrochloride (Standard)	Vasopressin Receptor Reference Standards	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Mozavaptan (hydrochloride) (Standard) is the analytical standard of Mozavaptan (hydrochloride). This product is intended for research and analytical applications. Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment ^[2].

HY-P5155

Stromatoxin 1	Potassium Channel	Neurological Disease
Stromatoxin 1 is an inhibitor of Potassium Channel, a peptide which can be isolated from tarantulas. Stromatoxin 1 selectively inhibits *K(V)2.1, K(V)2.2, K(V)4.2, and K(V)2.1/9.3 channels. K(V)2.1 and K(V)2*.2, but not K(V)4.2, channel subunits play a key role in opposing both myogenic and neurogenic urinary bladder smooth muscle (UBSM) contractions in rats .

HY-18346S

Mozavaptan-d6 OPC-31260-d₆	Isotope-Labeled Compounds Vasopressin Receptor	Metabolic Disease Endocrinology Cancer
Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment ^[2].

HY-P1809A

Velmupressin acetate c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2 acetate	Vasopressin Receptor	Metabolic Disease
Velmupressin (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) acetate is a potent, selective and short-acting peptidic V₂ receptor (V₂R) agonist with EC₅₀s of 0.07 and 0.02 nM for hV₂R and rV₂R, respectively .

HY-P1809

Velmupressin c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2	Vasopressin Receptor	Metabolic Disease
Velmupressin (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) is a potent, selective and short-acting peptidic V₂ receptor (V₂R) agonist with EC₅₀s of 0.07 and 0.02 nM for hV₂R and rV₂R, respectively .

HY-120285

M-0002 hydrochloride RWJ-351647 hydrochloride; SPD-556 hydrochloride	Endogenous Metabolite	Endocrinology
M-0002 hydrochloride (RWJ-351647 hydrochloride) is a biologically active compound that acts as an antagonist of the vasopressin V2 receptor. M-0002 hydrochloride is potentially useful for inhibiting ascites. M-0002 hydrochloride shows excellent properties that are favorable for clinical development .

HY-18347AR

Conivaptan hydrochloride (Standard) YM 087 (Standard)	Reference Standards Vasopressin Receptor	Cardiovascular Disease Endocrinology
Conivaptan (hydrochloride) (Standard) is the analytical standard of Conivaptan (hydrochloride). This product is intended for research and analytical applications. Conivaptan (hydrochloride) is a non-peptide antagonist of vasopressin receptor, with K_i values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.

HY-P991148

Moflerafusp alfa	PD-1/PD-L1	Cancer
Moflerafusp alfa is a fusion protein targeting the human signal regulatory protein α (SIRPα) variant V2 D1 domain and human programmed death ligand 1 (PD-L1). Moflerafusp alfa is promising for research of various cancers .

HY-129333

L-364918	Oxytocin Receptor Vasopressin Receptor	Metabolic Disease
L-364918 is a potent and selective oxytocin and arginine vasopressin antagonist with K_i values of 30, 1300, 2400 nM for OT, AVP-V1, AVP-V2, respectively. L-364918 has the potential for the research of preterm labor and disturbances in water balance .

HY-124733

LIT-001 free base	Oxytocin Receptor	Neurological Disease
LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC₅₀=55 nM; K_i=226 nM). LIT-001 free base improves social interaction in a mouse model of autism .

HY-165423

DM-4111	Vasopressin Receptor Drug Metabolite	Cardiovascular Disease
DM-4111, one of the major monohydroxyl metabolites of Tolvaptan (HY-17000), is a potent vasopressin V₂ receptor inhibitor. DM-4111 inhibits water reabsorption in the renal tubules, thereby promoting the excretion of electrolyte-free water. DM-4111 is promising for research of cardiovascular diseases ^[2].

HY-P5213

Vasopressin Dimer (parallel) TFA	Vasopressin Receptor Oxytocin Receptor	Endocrinology
Vasopressin Dimer (parallel) TFA is a parallel dimer of Vasopressin (HY-B1811). Vasopressin Dimer (parallel) TFA can activate four G protein-coupled receptors, V1aR, V1bR, *V2R, and OTR* .

HY-177099

Lorotomidate	GABA Receptor	Neurological Disease
Lorotomidate (Example 16) is a GABAA receptor agonist. Lorotomidate has anaesthetic effects (ED₅₀: i.v., 2 mg/kg in KM mice; LD₅₀: 46.5 mg/kg in KM mice). Lorotomidate has no inhibitory effect on the secretion of corticosteroids in animals, and thus has good safety .

Cat. No.	Product Name

HY-L0122V

Asinex CNS Macrocycles Library

1,122 compounds

Several CNS multi-parameter scoring approaches have been reported: CNS-MPO, CNS-MPO V.2, CNS-TEMPO, which suggesting an algorithm to predict CNS-ike properties of new chemical entities. We have applied these scoring algorithms to select macrocycles satisfying multiple cut-offs and structural desirability criteria. The resulting set consists of 1,122 macrocyclic compounds with CNS-MPO > 4, CNS-MPO.v2 > 4, and CNS-TEMPO < 4 for CNS-related drug discovery and research.

Cat. No.	Product Name	Target	Research Area

HY-P0049

Argipressin 5+ Cited Publications Arg8-vasopressin; AVP	Vasopressin Receptor	Neurological Disease Cancer
Argipressin (Arg8-vasopressin) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a K_d value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1.

HY-W539944

Argipressin acetate 5+ Cited Publications Arg8-vasopressin acetate; AVP acetate	Vasopressin Receptor Apoptosis	Neurological Disease Cancer
Argipressin (Arg8-vasopressin) (acetate) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a K_d value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1 ^[2] .

HY-P0272

Peptide T	HIV	Infection
Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

HY-P1390

d[Cha4]-AVP	Vasopressin Receptor	Endocrinology
d[Cha4]-AVP is a potent and selective vasopressin (AVP) V1b receptor agonist with a K_i of 1.2 nM for human V1b receptor. d[Cha4]-AVP shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors ^[2].

HY-162394

Vasopressin V2 receptor antagonist 2	Vasopressin Receptor	Metabolic Disease
Vasopressin V2 receptor antagonist 2 (Compound 33) is an antagonist of the arginine vasopressin V₂ receptor (V₂R) with a K_i value of 6.2 nM. Vasopressin V2 receptor antagonist 2 can effectively reduce cAMP levels, thereby inhibiting the growth of renal cysts[1].

HY-P0049A

Argipressin diacetate Arg8-vasopressin diacetate; AVP diacetate; ADH	Apoptosis Vasopressin Receptor	Neurological Disease Cancer
Argipressin (diacetate) (AVP (diacetate), also known as antidiuretic hormone (ADH)) is a 9 amino acid neuropeptide secreted by the posterior pituitary. Argipressin (diacetate) (AVP (diacetate)) can regulate the biological effects of fluid balance, osmolality and cardiovascular through three separate G-protein coupled receptors (GPCRs), namely Avpr1a (V1a), Avpr1b (V1b) and Avpr2 (V2). Argipressin (diacetate) (AVP (diacetate)) also have potentially important effects on centrally regulated metabolic processes .

HY-P0272A

Peptide T TFA	HIV	Infection
Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

HY-P1390A

d[Cha4]-AVP TFA	Vasopressin Receptor	Endocrinology
d[Cha4]-AVP TFA is a potent and selective vasopressin (AVP) V1b receptor agonist with a K_i of 1.2 nM for human V1b receptor. d[Cha4]-AVP TFA shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors ^[2].

HY-P1810

c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-Agm	Vasopressin Receptor	Neurological Disease
c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-Agm is a is a potent, selective and short-acting peptidic V₂ receptor (V₂R) agonist with EC₅₀s of 0.25 and 0.05 nM for hV₂R and rV₂R, respectively .

HY-P5155

Stromatoxin 1	Potassium Channel	Neurological Disease
Stromatoxin 1 is an inhibitor of Potassium Channel, a peptide which can be isolated from tarantulas. Stromatoxin 1 selectively inhibits *K(V)2.1, K(V)2.2, K(V)4.2, and K(V)2.1/9.3 channels. K(V)2.1 and K(V)2*.2, but not K(V)4.2, channel subunits play a key role in opposing both myogenic and neurogenic urinary bladder smooth muscle (UBSM) contractions in rats .

HY-P1809A

Velmupressin acetate c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2 acetate	Vasopressin Receptor	Metabolic Disease
Velmupressin (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) acetate is a potent, selective and short-acting peptidic V₂ receptor (V₂R) agonist with EC₅₀s of 0.07 and 0.02 nM for hV₂R and rV₂R, respectively .

HY-P1809

Velmupressin c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2	Vasopressin Receptor	Metabolic Disease
Velmupressin (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) is a potent, selective and short-acting peptidic V₂ receptor (V₂R) agonist with EC₅₀s of 0.07 and 0.02 nM for hV₂R and rV₂R, respectively .

HY-P5213

Vasopressin Dimer (parallel) TFA	Vasopressin Receptor Oxytocin Receptor	Endocrinology
Vasopressin Dimer (parallel) TFA is a parallel dimer of Vasopressin (HY-B1811). Vasopressin Dimer (parallel) TFA can activate four G protein-coupled receptors, V1aR, V1bR, *V2R, and OTR* .

HY-W104304

2-(3-Trifluoromethylphenyl)glycine hydrochloride	Vasopressin Receptor	Cardiovascular Disease
2-(3-Trifluoromethylphenyl)glycine hydrochloride is a precursor of substituted 2-acetamido-5-aryl-l, 2,4-triazolones. Substituted 2-acetamido-5-aryl-l, 2,4-triazolones are dual V1a/V2 receptor antagonists and can be used in cardiovascular disease research .

HY-P5010

(D-Arg8)-Inotocin	Vasopressin Receptor	Cardiovascular Disease
(D-Arg8)-Inotocin is a potent, selective and competitive antagonist of vasopressin receptor (V_1aR), with a K_i of 1.3 nM. (D-Arg8)-Inotocin shows more than 3000-fold selectivity for the human V1aR over the other three subtypes, OTR, V1bR and V2R .

HY-P5214

Vasopressin Dimer (anti-parallel) TFA	Vasopressin Receptor Oxytocin Receptor	Endocrinology
Vasopressin Dimer (anti-parallel) TFA is an anti-parallel dimer of Vasopressin (HY-B1811). Vasopressin Dimer (anti-parallel) TFA can activate four G protein-coupled receptors, V1aR, V1bR, *V2R, and OTR* .

HY-P11702

f-MFFINTLTL	Bacterial	Others
f-MFFINTLTL is a formylated nonapeptide and a natural ligand from mitochondria or bacteria. f-MFFINTLTL serves as a tool chemical stimulant for the specific activation of sensory neurons expressing the specific vomeronasal receptor (V2rf2) .

HY-P11701

SEIDLILGY	MHC	Others
SEIDLILGY is a nonapeptide identified as a peptide ligand derived from mouse major histocompatibility complex class I (MHC). SEIDLILGY serves as a tool chemical stimulant for the specific activation of sensory neurons expressing the particular vomeronasal receptor (V2rf2) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991148

Moflerafusp alfa	PD-1/PD-L1	Cancer
Moflerafusp alfa is a fusion protein targeting the human signal regulatory protein α (SIRPα) variant V2 D1 domain and human programmed death ligand 1 (PD-L1). Moflerafusp alfa is promising for research of various cancers .

HY-P992414

MS17-38	Inhibitory Antibodies	Cancer
MS17-38 is a monoclonal antibody targeting *PODXL-v2. MS17-38 binds to a specific conformational epitope of PODXL-v2* on gastric cancer cells, modulates target function, inhibits gastric cancer cell growth and migration, and blocks tumor growth and lung metastasis. MS17-38 can be used for the research of gastric cancer .

HY-P990986

Efdelikofusp alfa	Interleukin Related	Inflammation/Immunology Cancer
Efdelikofusp alfa is a bispecific Fc fusion protein. Efdelikofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efdelikofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.

HY-P990992

Efzilonkofusp alfa GI-102	Interleukin Related	Inflammation/Immunology Cancer
Efzilonkofusp alfa is a bispecific Fc fusion protein. Efzilonkofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efzilonkofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.

HY-P992346

DS-1103a	CD47	Cancer
DS-1103a is a humanized IgG4 monoclonal antibody targeting SIRPa/CD172a. DS-1103a inhibits the interaction between SIRPα and CD47. DS-1103a enhances antibody-dependent cellular phagocytosis of cancer cells. DS-1103a can be used for the research of solid tumors. The recommended isotype control is: Human IgG4 (S228P) kappa, (HY-P99003) .

Species:	Virus (1) Human (7)
Tag:	His (5) Strep (1) Tag Free (2) Avi (2) Fc (1)
Source:	HEK293 (4) Sf9 insect cells (2) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704083

	UBE2V2 Protein, Human Ubiquitin-Conjugating Enzyme E2 Variant 2; DDVit 1; Enterocyte Differentiation-Associated Factor 1; EDAF-1; Enterocyte Differentiation-Promoting Factor 1; EDPF-1; MMS2 Homolog; Vitamin D3-Inducible Protein; UBE2V2; MMS2; UEV2	Human	E. coli
	UBE2V2 protein lacks independent ubiquitin ligase activity and forms a functional heterodimer with UBE2N. Together, they catalyze nonclassical polyubiquitin chain synthesis ("Lys-63"), distinct from proteasome-driven degradation. UBE2V2 Protein, Human is the recombinant human-derived UBE2V2 protein, expressed by E. coli, with tag free.

HY-P71411

	UBE2V2 Protein, Human (His) Ubiquitin-Conjugating Enzyme E2 Variant 2; DDVit 1; Enterocyte Differentiation-Associated Factor 1; EDAF-1; Enterocyte Differentiation-Promoting Factor 1; EDPF-1; MMS2 Homolog; Vitamin D3-Inducible Protein; UBE2V2; MMS2; UEV2	Human	E. coli
	UBE2V2 protein lacks independent ubiquitin ligase activity and forms a functional heterodimer with UBE2N. Together, they catalyze nonclassical polyubiquitin chain synthesis ("Lys-63"), distinct from proteasome-driven degradation. UBE2V2 Protein, Human (His) is the recombinant human-derived UBE2V2 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P704084

	UBE2V2 Protein, Human (sf9) Ubiquitin-Conjugating Enzyme E2 Variant 2; DDVit 1; Enterocyte Differentiation-Associated Factor 1; EDAF-1; Enterocyte Differentiation-Promoting Factor 1; EDPF-1; MMS2 Homolog; Vitamin D3-Inducible Protein; UBE2V2; MMS2; UEV2	Human	Sf9 insect cells
	UBE2V2 protein lacks independent ubiquitin ligase activity and forms a functional heterodimer with UBE2N. Together, they catalyze nonclassical polyubiquitin chain synthesis ("Lys-63"), distinct from proteasome-driven degradation. UBE2V2 Protein, Human (sf9) is the recombinant human-derived UBE2V2 protein, expressed by Sf9 insect cells, with tag free.

HY-P704082

	UBE2V2 Protein, Human (sf9, His, strep) Ubiquitin-Conjugating Enzyme E2 Variant 2; DDVit 1; Enterocyte Differentiation-Associated Factor 1; EDAF-1; Enterocyte Differentiation-Promoting Factor 1; EDPF-1; MMS2 Homolog; Vitamin D3-Inducible Protein; UBE2V2; MMS2; UEV2	Human	Sf9 insect cells
	UBE2V2 protein lacks independent ubiquitin ligase activity and forms a functional heterodimer with UBE2N. Together, they catalyze nonclassical polyubiquitin chain synthesis ("Lys-63"), distinct from proteasome-driven degradation. UBE2V2 Protein, Human (sf9, His, strep) is the recombinant human-derived UBE2V2 protein, expressed by Sf9 insect cells, with N-His and N-Strep labeled tag.

HY-P705083

	SARS-CoV-2 S Trimer Protein (Biotinylated, B.1.351, HEK293, His-Avi) Spike; S protein; Spike glycoprotein; S glycoprotein; B.1.351; 20H/501Y.V2	Virus	HEK293

HY-P77836

	SIRP alpha V2/CD172a Protein, Human (HEK293, His) CD172a; BIT; MFR; MYD1; MYD-1; P84; PTPNS1; SHP substrate 1; SHPS1; SHPS-1; SHPS1CD172A; SIRP alpha; SIRPA; Sirp-alpha-1; SIRPalpha2; Sirp-alpha-2; Sirp-alpha-3	Human	HEK293
	SIRP alpha V2/CD172a Protein, Human (HEK293, His) is the recombinant human-derived SIRP alpha V2/CD172a protein, expressed by HEK293, with C-His labeled tag.

HY-P77837

	SIRP alpha V2/CD172a Protein, Human (HEK293, Fc) CD172a; BIT; MFR; MYD1; MYD-1; P84; PTPNS1; SHP substrate 1; SHPS1; SHPS-1; SHPS1CD172A; SIRP alpha; SIRPA; Sirp-alpha-1; SIRPalpha2; Sirp-alpha-2; Sirp-alpha-3	Human	HEK293
	SIRP alpha V2/CD172a Protein, Human (HEK293, Fc) is the recombinant human-derived SIRP alpha V2/CD172a protein, expressed by HEK293, with C-hFc labeled tag.

HY-P77840

	SIRP alpha V2/CD172a Protein, Human (Biotinylated, HEK293, His-Avi) CD172a; BIT; MFR; MYD1; MYD-1; P84; PTPNS1; SHP substrate 1; SHPS1; SHPS-1; SHPS1CD172A; SIRP alpha; SIRPA; Sirp-alpha-1; SIRPalpha2; Sirp-alpha-2; Sirp-alpha-3	Human	HEK293
	SIRP alpha V2/CD172a Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SIRP alpha V2/CD172a protein, expressed by HEK293, with C-Avi, C-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-18346S

Mozavaptan-d6

Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment ^[2].

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P89802

	CYP4V2 Antibody (YA9146)	WB, IP, ELISA	human
	CYP4V2 Antibody (YA9146) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CYP4V2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: